![](/img/cover-not-exists.png)
A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours
Scott, L, Soepenberg, O, Verweij, J, de Jonge, M., Th Planting, A., McGovern, D, Principe, P, Obach, R, Twelves, CVolume:
18
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdl439
Date:
November, 2006
File:
PDF, 147 KB
english, 2006